### Daunorubicin

**Section:** 8. Immunomodulators and antineoplastics  >  8.2. Antineoplastics and supportive medicines  >  8.2.1. Cytotoxic medicines

#### Essential medicine status

- **ATC codes:** L01DB02, EMLc
- **Indication:** Lymphoid leukaemia, not elsewhere classified
- **ICD11 code:** 2C03.3
- **INN:** Daunorubicin
- **Medicine type:** Chemical agent
- **List type:** Complementary (EML), (EMLc)

#### Formulations

- Parenteral > General injections > IV:
  - 50 mg in vial (as hydrochloride) powder for injection
  - 20 mg in vial (as hydrochloride) powder for injection
  - 2 mg per mL in vial (as hydrochloride)
  - 5 mg per mL in vial (as hydrochloride)

#### EML status history

- First added in 1999 (TRS 895)
- Changed in 2002 (TRS 914)
- Changed in 2007 (TRS 950)
- Changed in 2015 (TRS 994)
- Changed in 2023 (TRS 1049)

#### Sex

- All

#### Age

- Also recommended for children

#### Therapeutic alternatives

- The recommendation is for this specific medicine

#### Patent information

- Patents have expired in most jurisdictions
- Read more about patents.

#### Tags

- Cancer

#### Wikipedia

- Daunorubicin

#### DrugBank

- Daunorubicin

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of additional formulations of daunorubicin (injection 2 mg/mL and 5 mg/mL in vial and powder for injection 20 mg in vial) to the EML and EMLc.